Clopidogrel/aspirin - Yuhan

Drug Profile

Clopidogrel/aspirin - Yuhan

Alternative Names: Aspirin/clopidogel - Yuhan; YH 14659

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antiplatelets; Antipyretics; Pyridines; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Coronary disorders

Most Recent Events

  • 01 Apr 2012 Yuhan Corporation completes a Phase I trial for Coronary disorders (in healthy volunteers) in South Korea (NCT01657071)
  • 01 Mar 2012 Yuhan Corporation initiates enrolment in a Phase-I trial for Coronary disorders (in healthy volunteers) in South Korea
  • 31 Dec 2011 Yuhan completes a Phase-I trial in healthy volunteers in South Korea (NCT01422109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top